Title
Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group
Date Issued
01 December 2019
Access level
open access
Resource Type
review
Author(s)
Goodman D.
Crocker M.E.
Pervaiz F.
McCollum E.D.
Steenland K.
Simkovich S.M.
Miele C.H.
Hammitt L.L.
Herrera P.
Zar H.J.
Campbell H.
McCracken J.P.
Thompson L.M.
Rosa G.
Kirby M.A.
Garg S.
Thangavel G.
Thanasekaraan V.
Balakrishnan K.
King C.
Clasen T.
Checkley W.
Nambajimana A.
Pillarisetti A.
Verma A.
Lovvorn A.
Diaz A.
Papageorghiou A.
Toenjes A.
Quinn A.
Nizam A.
Ryan B.
Young B.
Barr D.
Canuz E.
Puzzolo E.
McCollum E.
Mollinedo E.
Majorin F.
Ndagijimana F.
Chang H.
Fuentes I.
Ntivuguruzwa J.D.
Uwizeyimana J.
Peel J.
Sarnat J.
Liao J.
McCracken J.P.
Rosenthal J.
Espinoza J.
Campbell J.M.
Smith K.
Mukhopadhyay K.
Waller L.
Moulton L.
Jaacks L.
Underhill L.
de la Fuentes L.
Elon L.
Thompson L.M.
Naeher L.
Clark M.
Laws M.
Howard M.
Crocker M.
Johnson M.
Kirby M.
Puttaswamy N.
De Leon O.
Craik R.
Merrick R.
Piedrahita R.
Sambandam S.
Rajkumar S.
Gupton S.
Hossen S.
Sinharoy S.
Jabbarzadeh S.
Harvey S.
Simkovich S.M.
Ramakrishnan U.
Burrowes V.
Davila-Roman V.
Aravindalochanan V.
Chen Y.
Sakas Z.
Publisher(s)
Lancet Publishing Group
Abstract
Pneumonia is a leading killer of children younger than 5 years despite high vaccination coverage, improved nutrition, and widespread implementation of the Integrated Management of Childhood Illnesses algorithm. Assessing the effect of interventions on childhood pneumonia is challenging because the choice of case definition and surveillance approach can affect the identification of pneumonia substantially. In anticipation of an intervention trial aimed to reduce childhood pneumonia by lowering household air pollution, we created a working group to provide recommendations regarding study design and implementation. We suggest to, first, select a standard case definition that combines acute (≤14 days) respiratory symptoms and signs and general danger signs with ancillary tests (such as chest imaging and pulse oximetry) to improve pneumonia identification; second, to prioritise active hospital-based pneumonia surveillance over passive case finding or home-based surveillance to reduce the risk of non-differential misclassification of pneumonia and, as a result, a reduced effect size in a randomised trial; and, lastly, to consider longitudinal follow-up of children younger than 1 year, as this age group has the highest incidence of severe pneumonia.
Start page
1068
End page
1083
Volume
7
Issue
12
Language
English
OCDE Knowledge area
Sistema respiratorio Políticas de salud, Servicios de salud
Scopus EID
2-s2.0-85075417439
PubMed ID
Source
The Lancet Respiratory Medicine
ISSN of the container
22132600
Sponsor(s)
We would like to thank all speakers who attended the “Challenges in the diagnosis of pneumonia in community-based intervention field trials” meetings held in Baltimore, MD, and Bethesda, MD, USA, in March, 2017, and February, 2018. Declaration of interests, LLH reports grants to her institution from Pfizer, Merck, GlaxoSmithKlein, and Novavax, outside of the submitted work. HC reports grants and personal fees from WHO and Bill & Melinda Gates Foundation, grants from the Innovative Medicines Initiative (a public-private partnership between the EU, represented by the European Commission, and the European Federation for Pharmaceutical Industries and Associations) Cancer Research UK, Sanofi, and National Institute for Health Research. EDM reports grants to his institution from the National Institutes of Health, Bill & Melinda Gates Foundation, and GlaxoSmithKlein outside of the submitted work. HJZ reports grants from the Bill & Melinda Gates Foundation. All other authors declare no competi ... LLH reports grants to her institution from Pfizer, Merck, GlaxoSmithKlein, and Novavax, outside of the submitted work. HC reports grants and personal fees from WHO and Bill & Melinda Gates Foundation, grants from the Innovative Medicines Initiative (a public-private partnership between the EU, represented by the European Commission, and the European Federation for Pharmaceutical Industries and Associations) Cancer Research UK, Sanofi, and National Institute for Health Research. EDM reports grants to his institution from the National Institutes of Health, Bill & Melinda Gates Foundation, and GlaxoSmithKlein outside of the submitted work. HJZ reports grants from the Bill & Melinda Gates Foundation. All other authors declare no competing interests. We received financial support from the US National Institutes of Health (NIH) in collaboration with the Bill & Melinda Gates Foundation. Participating NIH organisations include the National Heart, Lung and Blood Institute, National Institute of ...
Sources of information: Directorio de Producción Científica Scopus